National Pension Service Has $381.88 Million Stock Position in Abbott Laboratories $ABT

Key Points

• National Pension Service increased its Abbott Laboratories position by 2.8% in the second quarter, owning 4.21 million shares valued at approximately $381.9 million. Institutional investors collectively hold 75.18% of Abbott’s stock.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $119.50, despite several firms recently lowering their targets.
• Abbott exceeded quarterly expectations with $1.31 in EPS and $12.59 billion in revenue, while maintaining a quarterly dividend of $0.63 per share, equivalent to a 2.4% annual yield.

National Pension Service lifted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 2.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,208,467 shares of the healthcare product maker's stock after purchasing an additional 114,105 shares during the period. National Pension Service owned 0.24% of Abbott Laboratories worth $381,876,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the 4th quarter worth $25,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $26,000. Institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a research report on Wednesday, May 27th. UBS Group dropped their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday, July 28th. Piper Sandler reiterated an "overweight" rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Weiss Ratings raised shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 6th. Finally, BTIG Research boosted their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $119.50.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s TactiFlex Duo Ablation Catheter, Sensor Enabled, for treating challenging cases of atrial fibrillation. The catheter combines pulsed-field ablation (PFA) and radiofrequency (RF) energy, giving physicians greater flexibility and expanding Abbott’s cardiac rhythm-management portfolio. The device previously received a European CE mark in January 2026, and U.S. approval could support broader adoption and future revenue growth. Abbott’s dual ablation catheter lands FDA approval
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating on Abbott and maintained a $135 price target, indicating substantial potential upside from recent trading levels. The endorsement suggests the firm views Abbott’s product pipeline and long-term fundamentals favorably. TD Cowen reaffirms Abbott buy rating
• Neutral Sentiment: A comparison of Abbott and Envista focuses on which medical-products stock offers better value. Abbott’s established business and growth prospects remain attractive, but its valuation may make it less compelling to investors specifically seeking undervalued shares. NVST or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Abbott was highlighted as a potential defensive “Dividend King,” supported by a 54-year dividend-growth streak and healthcare-related catalysts. This may appeal to income-focused investors, although the article is general commentary rather than a new company announcement. If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King
• Negative Sentiment: Abbott recently underperformed the broader market in a prior session, reflecting near-term selling pressure. The decline appears market- or sentiment-driven rather than tied to a deterioration in the company’s fundamentals, but it may be tempering the immediate reaction to the FDA news. Here’s Why Abbott Fell More Than the Broader Market

Abbott Laboratories Trading Down 0.2%

Shares of ABT stock opened at $105.29 on Thursday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The stock has a 50 day simple moving average of $105.30 and a two-hundred day simple moving average of $99.90. The company has a market cap of $182.19 billion, a P/E ratio of 34.07, a PEG ratio of 1.96 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.